Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK-7965

Known as: CDK inhibitor SCH 727965 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Neuroblastoma (NB), the most common extracranial solid tumor of childhood, is responsible for approximately 15% of cancer-related… Expand
Is this relevant?
2015
2015
KRAS is activated by mutation in the vast majority of cases of pancreatic cancer; unfortunately, therapeutic attempts to inhibit… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
INTRODUCTION Effective therapies after failure of treatment with anthracyclines and taxanes are needed for patients with… Expand
Is this relevant?
2014
2014
OBJECTIVES Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclin-dependent kinases, has been… Expand
Is this relevant?
Review
2014
Review
2014
INTRODUCTION Cyclin-dependent kinases (CDK) represent attractive targets in oncology due to their key role in controlling gene… Expand
Is this relevant?
2013
2013
  • J. Stephensona, John Nemunaitisb, +9 authors Martin J. Edelmane
  • 2013
Objectives: Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclindependent kinases, has been… Expand
  • table 2
  • figure 2
  • table 3
  • table 4
Is this relevant?
2012
2012
After more than a decade of clinical development for cancer and numerous failures, Phase III trials of cyclin-dependent kinase… Expand
Is this relevant?